On June 4, Hansoh Pharmaceutical announced that its New Drug Application (NDA) for once-weekly subcutaneous injection of GLP-1/GIP receptor dual agonist ollipopeptide injection has been accepted by the National Medical Products Administration (NMPA) of China. The drug is indicated for long-term weight management in obese or overweight adults.

Olepoeptide (HS-20094) is a glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic peptide (GIP) dual receptor agonist independently developed by Hansoh Pharmaceutical . It selectively activates GLP-1/GIP receptors to regulate metabolic pathways related to appetite control, glucose metabolism and energy balance, producing biological effects such as blood sugar control and weight loss. It is administered once a week via subcutaneous injection.

According to a press release from Hansoh Pharmaceutical, in March 2026, the first Phase 3 clinical trial (HS-20094-301) of olepiropeptide in overweight or obese adults in China met its primary endpoint. After 48 weeks of treatment with olepiropeptide, the highest average weight loss from baseline was 19.3%, with the highest proportion of subjects achieving a weight loss of ≥5% reaching 97.2%. The study showed excellent gastrointestinal tolerability in the olepiropeptide treatment group, with an average incidence of nausea <10% and an average incidence of vomiting <5%. Compared with published Phase 3 trial data for GLP-1-related dual agonists, the incidence of gastrointestinal adverse events and treatment discontinuation rates were lower.

On June 2, 2025, Hansoh Pharmaceutical announced that it had entered into a licensing agreement with Regeneron Pharmaceuticals, granting Regeneron a worldwide exclusive license (excluding Mainland China, Hong Kong and Macau) to develop, manufacture and commercialize HS-20094.

https://mp.weixin.qq.com/s/ewvLBSdn2CfuxrBX0fSMXQ